JUST IN　•　TechCrunch

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

SHARE THIS STORYPLUS UNLOCKS FAVORITES READ LATER AND SOURCE CONTROL

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

READ ORIGINAL REPORT ↗

THIS JUST HAPPENED PACKAGES THE WORLD INTO A FAST LIVE FEED SOURCE REPORTING STAYS ONE CLICK AWAY

RELATED POSTSMORE TECH

TECH　•　MarketWatch.com - Top Stories

McDonald’s is making a historic bet on chicken — and AI — to bring back customers

TECH　•　Engadget - Technology News & Expert Reviews

Microsoft's new Surface Pro 12 and Surface Laptop 13 feature Snapdragon X2 Plus chips

TECH　•　The Verge

Microsoft refreshes its smaller Surface Pro and Laptop with Qualcomm’s X2 Plus

TECH　•　The Verge

Microsoft’s new Surface Mouse has haptic feedback and a customizable action button

TECH　•　Ars Technica - All content

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

McDonald’s is making a historic bet on chicken — and AI — to bring back customers

Microsoft's new Surface Pro 12 and Surface Laptop 13 feature Snapdragon X2 Plus chips

Microsoft refreshes its smaller Surface Pro and Laptop with Qualcomm’s X2 Plus

Microsoft’s new Surface Mouse has haptic feedback and a customizable action button

XPRIZE Wildfire winners spotted fires within 10 min—but couldn’t stop them

Discord age verification rolls out today with changes spurred by user backlash

Micron’s stock has become a ‘battleground’ as the AI narrative shifts

YouTube promises custom feeds and a lot more AI later this year